How shall we use the proteomics toolbox for biomarker discovery?

Biomarker discovery for clinical purposes is one of the major areas in which proteomics is used. However, despite considerable effort, the successes have been relatively scarce. In this perspective paper, we try to highlight and analyze the main causes for this limited success, and to suggest alternate strategies, which will avoid them, without eluding the foreseeable weak points of these strategies. Two major strategies are analyzed, namely, the switch from body fluids to cell and tissues for the initial biomarker discovery step or, if body fluids must be analyzed, the implementation of highly selective protein selection strategies.

💡 Research Summary

The paper provides a critical examination of why proteomics‑driven biomarker discovery for clinical use has yielded relatively few successes despite substantial effort. It begins by acknowledging the unique advantage of proteomics—direct measurement of functional proteins—as opposed to genomics or transcriptomics, but quickly points out that the translation of discovery findings into validated, market‑ready biomarkers has been limited. The authors identify four principal obstacles. First, the extreme dynamic range of body fluids such as plasma or serum (spanning six to eight orders of magnitude) causes low‑abundance disease‑related proteins to be masked by highly abundant carriers like albumin and immunoglobulins. Second, pre‑analytical variability—including collection timing, anticoagulant choice, storage conditions, and freeze‑thaw cycles—introduces inconsistencies that undermine reproducibility. Third, a disconnect exists between discovery and validation phases: discovery often relies on label‑based quantitative methods (e.g., TMT, SILAC) while validation uses targeted assays (ELISA, MRM), leading to mismatched quantitation thresholds and loss of candidates. Fourth, statistical rigor is frequently insufficient; many studies fail to adequately correct for multiple testing or to power their experiments, resulting in a high false‑positive rate.

To overcome these challenges, the authors propose two alternative strategies. The first strategy shifts the initial discovery step from body fluids to cells or tissues. Tissue samples reflect disease‑specific protein expression changes more directly, and modern technologies such as laser capture microdissection (LCM) and single‑cell proteomics enable precise isolation of pathological regions and heterogeneous cell populations. This approach can improve detection of low‑abundance biomarkers and capture disease‑specific post‑translational modifications. However, tissue acquisition is invasive, standardizing histological differences between cases and controls is difficult, and fixation processes can introduce artefacts.

The second strategy retains fluid analysis but incorporates highly selective protein enrichment techniques. By using affinity reagents—high‑quality antibodies, aptamers, or chemically engineered probes—researchers can pre‑concentrate target protein subsets, thereby compressing the dynamic range and enhancing sensitivity. The paper highlights the utility of enrichment for disease‑specific modifications (phosphorylation, glycosylation) and for capturing multiplexed biomarker panels through multi‑affinity or switchable capture systems. While this method can dramatically improve detection limits, it also raises concerns about reagent cost, batch‑to‑batch variability, and potential non‑specific binding that could confound downstream validation.

Both strategies, the authors argue, must be coupled with rigorous, large‑scale validation across multiple cohorts and institutions. Standardized sample handling protocols, unified data‑processing pipelines, and open repositories (e.g., PRIDE, PeptideAtlas) are essential for reproducibility. Moreover, the transition from analytical validity to clinical validity and ultimately clinical utility should follow a staged framework, ensuring that each candidate biomarker is vetted for performance, clinical relevance, and cost‑effectiveness before implementation.

In conclusion, the limited success of proteomics in biomarker discovery is not solely a technical issue but also reflects gaps in research culture, infrastructure, and regulatory alignment. The paper calls for coordinated efforts among scientists, clinicians, industry, and regulatory bodies to establish standardized workflows, robust validation frameworks, and sustainable data‑sharing practices. Only through such systemic changes can the full potential of the proteomics toolbox be realized for reliable, clinically actionable biomarker discovery.